Mallia Therapeutics Presents New Alopecia Treatment at EHRS

Mallia Therapeutics GmbH has unveiled an innovative approach for treating alopecia at the European Hair Research Society's (EHRS) annual meeting in Warsaw. CEO Prof. Dr. Alexander Steinkasserer will discuss the company's proprietary use of soluble CD83 (sCD83) as a novel therapy during the conference session on May 30. The approach is based on sCD83's capability to stimulate hair growth and prolong the anagen phase of hair follicles.

sCD83, an immune-modulatory protein, shows promise in promoting hair regeneration by facilitating inflammation resolution and energizing regulatory T cells. Unlike other topical treatments, sCD83 acts locally without entering the bloodstream, diminishing the risk of systemic side effects. The method targets both androgenetic alopecia and alopecia areata, broadening its applicability for diverse hair loss concerns.